Reduced prostacyclin activity in systemic lupus erythematosus.
Authors:
- B.A McVerryBMB.A McVerry
- S.J MachinSMS.J Machin
- H ParryHPH Parry
- A.H GoldstoneAGA.H Goldstone
Open Access
- 1 October 1980
- journal article
- case report
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 39 (5) , 524-525
Abstract
When fresh rabbit aorta is incubated with plasma, prostacyclin, a potent inhibitor of platelet aggregation, is normally released. Plasma obtained from 2 patients with systemic lupus erythematosus (SLE) inhibited prostacyclin activity, while plasma from 22 other patients with SLE and 40 normal control subjects showed normal activity. Absence of prostacyclin activity did not appear to correlate with the clinical severity of the underlying disease. The possible association of this finding and the presence of thrombotic lesions in both patients is discussed.Keywords
This publication has 6 references indexed in Scilit:
- Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendotheliumBlood, 1979
- PROSTACYCLIN (PROSTAGLANDIN-I2, PROSTAGLANDIN-PGI2 INHIBITS PLATELET-ADHESION AND THROMBUS FORMATION ON SUBENDOTHELIUM1979
- HqMOLYTIC-URqMIC SYNDROME: DEFICIENCY OF PLASMA FACTOR(S) REGULATING PROSTACYCLIN ACTIVITY?The Lancet, 1978
- HUMAN ARTERIAL AND VENOUS TISSUES GENERATE PROSTACYCLIN (PROSTAGLANDIN X), A POTENT INHIBITOR OF PLATELET AGGREGATIONThe Lancet, 1977
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976
- Thrombosis of Renal Veins and Inferior Vena Cava Complicating Lupus NephritisJAMA, 1968